DARMSTADT, Germany–(BUSINESS WIRE)–Merck KGaA, Darmstadt, Germany, which operates its Healthcare business as EMD Serono in the US and Canada, today announced it has strengthened its Oncology franchise by regaining exclusive worldwide rights to develop, manufacture, and commercialize anti-programmed death ligand-1 (PD-L1) antibody BAVENCIO® (avelumab) following the termination of its Alliance agreement with Pfizer. “On behalf of Merck KGaA, Darmstadt, Germany, I’d like to thank Pfizer for thei My Business Wire News
